Your session is about to expire
← Back to Search
Topical Insulin Drops for Glaucoma
Study Summary
This trial will study the safety of using insulin to treat glaucoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I have severe vision loss due to eye conditions other than glaucoma.You follow a vegan diet.I have a history of heart disease or irregular heartbeats.My blood sugar levels are high, indicating I may have diabetes or glucose intolerance.I have been diagnosed with moderate glaucoma.I do not have active infections like HIV, TB, hepatitis, or sepsis causing potassium loss.I am able to understand and agree to the study's procedures and risks.I have inflammatory bowel disease.I am taking medications that could lower my potassium levels.I sweat excessively.I frequently urinate large amounts.You have a special diet that restricts certain types of food.I have an eating disorder like anorexia or bulimia that could lead to malnutrition.You have had an allergic reaction to insulin or any of the ingredients in the medication before.I have a tumor that produces insulin.I am either under 18 or over 75 years old.I am unable to understand and agree to the study's details on my own.I haven't had eye surgery in the last 6 months.I am able to attend all required tests and follow-ups for the study.I have a kidney condition that causes me to lose salt.I need plasmapheresis for my blood or inflammatory condition.Only my worse eye will be treated in the study.I had cataract surgery within the last 3 months.I am on a low-potassium diet due to a medical condition.I have chronic kidney disease, with or without dialysis.I have cirrhosis or another liver disease like hepatitis B or C.You have a disability that limits your ability to eat a balanced diet and get enough nutrients.I am between 18 and 75 years old.I have a condition that can lead to low potassium levels, like Cushing's disease.I have been diagnosed with moderate open-angle glaucoma.You have a problem with drinking too much alcohol.I have a condition that increases my risk of low potassium or blood sugar.
- Group 1: Topical insulin
- Group 2: Topical artificial tears
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the participant population size of this experiment?
"This medical trial is not presently accepting applications. It was first posted on February 1st 2023, with the last update occurring November 29th 2022. For those looking to join a clinical study, there are 215 research trials for glaucoma and 72 studies recruiting candidates for Topical insulin available right now."
Are there available slots to join this investigation?
"Data on clinicaltrials.gov attests that this particular trial is not presently accepting new applicants. Initially posted on February 1st 2023, the most recent update was made in November of 2022. Despite its lack of recruitment at present time, there are still 287 other medical studies actively enrolling patients."
Has Topical insulin been investigated in any other research endeavors?
"Presently, there are 72 active Topical insulin trials with 13 at Phase 3. Most of the studies for this substance take place in Sao Luis, MA; however, a total of 248 clinical trial sites have included research on topical insulin."
What potential risks exist when using topical insulin treatments?
"Due to the limited success of prior clinical trials, Topical insulin is estimated to be relatively unsafe on a scale from 1-3. This medical trial being classified as Phase 1 implies there has been little data supporting its efficacy or safety."
What is the main aim of this clinical trial?
"Over the course of a 12 month period, this trial will track Rate of Hypoglycemia as its primary outcome. Furthermore, it will also measure P50-N95 amplitude on PERG; PERG P50 implicit time; and Snellen chart visual acuity expressed in logMAR to establish secondary outcomes."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger